← Back to Clinical Trials
Recruiting NCT02954419

NCT02954419 IgA Nephropathy Biomarkers Evaluation Study (INTEREST)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02954419
Status Recruiting
Phase
Sponsor Sun Yat-sen University
Condition IgA Nephropathy
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2016-11
Primary Completion 2026-11

Eligibility & Interventions

Sex All sexes
Min Age 14 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
No intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2016-11 with a primary completion date of 2026-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This prospective cohort study is designed to examine the association between blood and urine biomarkers (including genetic variants) and long-term kidney disease progression among 2000 Chinese IgA nephropathy patients with relatively normal kidney function (eGFR≥60 ml/min/1.73 m2).

Eligibility Criteria

Inclusion Criteria: * Male or female individuals aged 14 years or older * Patients with biopsy-proven primary IgA nephropathy * A renal biopsy available for reviewing must include 10 or more glomeruli. * The first renal biopsy was performed within 3 years. * eGFR ≥ 60 ml/min/1.73 m2 (MDRD formula); * Individuals or their legal representative who are able to understand and have voluntarily signed the informed consent form (ICF). Exclusion Criteria: * Relatives were diagnosed with biopsy-proven primary IgA nephropathy; * Individuals had secondary IgA nephropathy due to diseases such as diabetes, chronic liver disease and systemic lupus erythematosus.

Contact & Investigator

Central Contact

Xue Qing Yu, M.D. & Ph.D.

✉ yuxq@mail.sysu.edu.cn

📞 8620-87766335

Principal Investigator

Xue Qing Yu, M.D. & Ph.D.

PRINCIPAL INVESTIGATOR

First Affiliated Hospital, Sun Yat-Sen University

Frequently Asked Questions

Who can join the NCT02954419 clinical trial?

This trial is open to participants of all sexes, aged 14 Years or older, studying IgA Nephropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02954419 currently recruiting?

Yes, NCT02954419 is actively recruiting participants. Contact the research team at yuxq@mail.sysu.edu.cn for enrollment information.

Where is the NCT02954419 trial being conducted?

This trial is being conducted at Guangzhou, China.

Who is sponsoring the NCT02954419 clinical trial?

NCT02954419 is sponsored by Sun Yat-sen University. The principal investigator is Xue Qing Yu, M.D. & Ph.D. at First Affiliated Hospital, Sun Yat-Sen University. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology